# ACT-1 (NCT00646854)

> Alemtuzumab and CHOP in T-cell Lymphoma

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT00646854
- Phase: PHASE3
- Status: COMPLETED
- Sponsor: Aarhus University Hospital
- Conditions: Lymphoma, T-Cell, Peripheral
- Interventions: CHOP14 chemotherapy (cyclophosphamide, hydroxydaunorubicin, vincristin, prednison) plus G-CSF, combined with alemtuzumab; CHOP14 chemotherapy (see specification under Arm B) plus G-CSF
- Enrollment: 136
- Primary outcome: Event-free Survival

## Preliminary discovery

Commentary in our index that names this trial so far. Final coverage is set when the report is built.

- X threads: 2
- YouTube: 1

## Order

Focused, $750, price fixed at order: https://www.erudio.com/contact?report=act-1-nct00646854